Newswise — HOUSTON ― A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows encouraging results for the treatment of osteosarcoma.
Findings from the study were presented today by Yifei Wang, M.D., a postdoctoral fellow of Pediatrics Research, at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The study was led by Richard Gorlick, M.D., chair and division head of Pediatrics.
Osteosarcoma is the most common type of bone tumor in adolescents and young adults. The outcome of patients with osteosarcoma has not improved in the last several decades ― since the implementation of adjuvant chemotherapy. For patients who are unable to tolerate the side effects of chemotherapy, few alternative treatments are available. While novel immunotherapies have shown promising efficacy in hematologic malignancies, like leukemia and lymphoma, little progress has been made in recent years for osteosarcoma.
“It’s a novel approach for osteosarcoma and we now have the opportunity to explore new treatment options,” Gorlick said. “This discovery represents a paradigm shift that will help us to move forward more rapidly. I anticipate that there will be an influx of other drugs that can be tested, and because the drugs are targeted to a particular surface protein, they are potentially more effective and have fewer side effects.”
In this study, researchers developed an integrated bioinformatic approach using proteomic and transcriptomic data compiled from the profiling data of osteosarcoma cell lines, mouse models, hundreds of patient tumor samples and thousands of normal human tissues. This approach identified surface proteins that are highly expressed on the osteosarcoma cell surface, but not in the normal tissues. Results from the analytical laboratory technique confirmed specific proteins could be targeted therapeutically by ADC or BTC.
The team had previously identified four surface proteins, MT1-MMP, MRC2, CD276 and LRRC15, that were highly expressed on the cell surface of osteosarcoma, but not in the normal human tissues. An earlier evaluation of CD276 and LRRC15 targeted ADC showed encouraging antitumor activity, validating the research team’s approach.
In this study, researchers focused on MT1-MMP as a drug target, validating the expression of the target in patient samples. They then tested an MT1-MMP targeted BTC, BT1769, in preclinical osteosarcoma mouse models. The drug proved to be highly active in the preclinical test, with 50% of the mice showing a 100% improved response.
“We are excited by these results because this target and drug have not been previously reported in osteosarcoma,” Wang said. “This is the first in a series of other proteins that have been identified by the same method.”
If successful in clinical trials, this research may bring new opportunities for the treatment of osteosarcoma, with higher efficacy and minimal toxicity exposure. Gorlick and his lab also are working with MD Anderson’s Therapeutics Discovery team on new approaches for targeting antibodies.
This work was funded by National Institutes of Health (NIH)/National Cancer Institute (NCI) (5U01CA199221-06), Swim Across America, The Foster Foundation, the Terry Fox Foundation, an Osteosarcoma Institute Translational and Preclinical grant, and the Barbara Epstein Foundation. MD Anderson Cancer Center’s Proteomics Facility was funded in part by NIH/NCI Cancer Center Support Grant (P30CA016672), NIH High End Instrumentation program grant (1S10OD012304-01), and Cancer Prevention and Research Institute of Texas Core Facility Grant (RP130397). NIH/NCI Cancer Center Support Grant (P30CA016672) also supported the Clinical Trials Office and the Bioinformatics Shared Resource.
In addition to Gorlick and Wang, MD Anderson authors include Jonathan Gill, M.D., Michael Roth, M.D., Douglas Harrison, M.D., Pooja Hingorani, M.D., Zhachui Xu, Xiangjun Tian, Ph.D., Jing Wang, Ph.D., Rossana Lazcano Segura, M.D., Alexander Lazar, M.D., Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Sylvester Jusu and Sankaranarayanan Kannan, DPHIL. Other authors include Edward A. Kolb, M.D., of Nemours Alfred I. duPont Hospital for Children; Raushan Kurmasheva, Ph.D., and Peter Houghton, Ph.D., of Greehey Children’s Cancer Research Institute; Eric Earley and Stephen Erickson of RTI International; Malcolm A. Smith, M.D., Ph.D., of National Cancer Institute; and Tara Gelb, Philip Huxley, Johanna Lahdenranta and Gemma Mudd of Bicycle Therapeutics. A full list of author disclosures can be found here.
- 30 -
About MD AndersonThe University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 49 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990 and has ranked first 14 times in the last 17 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).